Admera Health Wins Top Honors from Frost & Sullivan in Technology Innovation for its Groundbreaking NGS-based Molecular Diagnostics
Admera Health is transforming precision medicine by covering a diverse range of indications with its flagship PGxOne™ Plus pharmacogenomics test
MOUNTAIN VIEW, Calif., Dec. 20, 2016 /PRNewswire/ -- Admera Health has been awarded the 2016 North American Frost & Sullivan Award for Technology Innovation for delivering a range of tests to the next-generation sequencing (NGS) molecular diagnostics market. These tests include PGxOne™ Plus for pharmacogenomics, a Cardiovascular Test Portfolio and a growing Oncology Test Portfolio. These products have proved highly valuable across the entire continuum of patient care, starting from screening, diagnosis, treatment to monitoring and patient management.
Click here to view the complete Frost Multimedia Wire: http://best-practices.frost-multimedia-wire.com/admera-health/
"Admera's flagship PGxOne™ Plus pharmacogenomics test conducts a comprehensive analysis of nearly 200 variants in 50 genes to gauge the way a patient will respond to specific drugs," said Frost & Sullivan Senior Research Analyst Madhumitha Rangesa. "Based on the patient's genetic makeup, the PGxOne™ Plus recommends more than 220 commercial drugs for pain management, cardiovascular disease, psychiatry, cancer and other indications."
PGxOne™ Plus report recommendations include considering alternatives when specific drugs should be avoided, dosage adjustment information when available, use with caution, and normal response expected. The clinically relevant results can help guide treatment decisions, which can potentially improve patient care and reduce adverse drug events.
Similarly, Admera's genetic testing for inherited cardiovascular diseases, CardioGxOne™, provides clear interpretations for disease diagnosis and the risk assessment of sudden cardiac death. The company also offers cancer testing such as the OncoGxOne™ and OncoGxSelect™. The former is a comprehensive cancer panel that detects a range of genomic variations related to targeted therapies and chemotherapeutic response across multiple cancer types, while the latter aligns with well-established and medically actionable guidelines. Admera has also developed non-invasive cancer mutation detection that analyzes circulated tumor DNA (ctDNA). This liquid biopsy technology can be utilized to guide cancer treatment selection and subsequent patient monitoring.
Apart from these products, Admera is creating multiple solutions with high commercialization potential. For instance, AtheroGxOne™, a gene panel specifically for the risk assessment and diagnosis of premature coronary or atherosclerotic disease was launched in
April 2016 at the American College of Cardiology.
Acknowledging the importance of collaborations to gain a competitive edge, Admera has partnered with WaferGen Biosystems to increase the coverage of the PGxOne™ Plus test. It also has partnerships with the cardiovascular genetics company Health in Code, Rosetta Genomics in the oncology space and has collaborated with hc1® Healthcare Relationship Cloud® to leverage its CRM solutions.
"Admera's multiple partnerships support its product marketing and distribution initiatives, as well as help it avail the services of healthcare client management experts," noted Rangesa. "Its fully automated bioinformatics technology platform has uniquely positioned it to compete in the promising digital health management space."
Admera's expansive product range and rapidly growing pipeline will reduce the overall cost burden of healthcare, making it richly deserving of the 2016 North American Frost & Sullivan Award for Technology Innovation.
Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend towards innovation, its relevance to the industry, and the positive impact on brand perception.
Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for outstanding achievement in areas such as leadership, technological innovation, customer service, and product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research.
About Admera Health
Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.
Contact:
Chiara Carella
P: +44 (0) 207.343.8314
F: 210.348.1003
E: [email protected]
Admera Health
Brady Millican
VP, Business Development
P: 908.222.0533
E: [email protected]
SOURCE Frost & Sullivan
Share this article